论文部分内容阅读
一九四九年Bal6＆Banga在人的胰脏中发现了弹性蛋白酶制剂的主成分-弹性蛋白酶。他们观察到动脉硬化症患者和老年人较之健康人和年轻人的胰脏中的弹性酶活性显著减少或消失这个事实;报告了弹性蛋白酶是担负着血管弹性纤维代谢的重要的酶。此后又弄清楚了由于弹性蛋白酶能够生理性地除去动脉硬化斑块上已变性、老化的弹性蛋白,促进新鲜的弹性蛋白生成,从而保持血管壁的正常;进而又由于它能生理性地调节代谢障碍的动脉管壁的脂质等成分,从而改善血液以及动脉管壁的脂质代谢。卫材确立了弹性蛋白酶成分的提取,精制方法,证实了口服可被吸收之后,弹性蛋白酶作为一种血管代谢剂创制成功了。
In 1949, Bal6 & Banga found the major component of elastase preparations, elastase, in human pancreas. They observed the fact that elastase activity in the pancreas of patients with atherosclerosis and the elderly significantly decreased or disappeared compared with healthy people and young people; elastase was reported to be an important enzyme responsible for the metabolism of blood vessel elastic fibers. Since then, it has also been clarified that since elastase can physiologically remove the denatured and aged elastin at the plaques of atherosclerosis and promote the production of fresh elastin so as to maintain the normal of the blood vessel wall, and in turn, it can regulate metabolism physiologically Obstructive arterial wall lipid and other ingredients, thereby improving the blood and arterial wall lipid metabolism. Eisai established the extraction of elastase components, purification methods, confirmed that oral can be absorbed, elastase as a vascular metabolic agent successfully created.